The first participant to receive partial cellular reprogramming for eye disease (advanced glaucoma) in a pilot study of 12 patients was treated. Using 3 of the 4 Yamanaka stem cell factors to potentially achieve cellular rejuvenation @Nature nature.com/articles/d41586-0…

This week, United in Vision brings together the best of the Foundation Fighting Blindness VISIONS Conference and the @Retina_Int World Congress for an unforgettable global gathering. Researchers. Clinicians. Industry leaders. Advocates. Individuals and families affected by blinding diseases. Together, we'll explore groundbreaking research, emerging therapies, and the latest innovations in assistive technologies, products, and services—all united by a shared commitment to advancing treatments and cures for blinding diseases. As we prepare to kick off this historic event, we're looking back at some of the incredible moments from VISIONS 2024. Will you be joining us in Fort Worth, Texas? Let us know where you're traveling from!

Preserving lean mass during tirzepatide (Zepbound) treatment. A randomized trial of a myostatin inhibitor for muscle mass building shows proof-of-concept. A 55% retention of lean mass compared with placebo nature.com/articles/s41591-0… just published @NatureMedicine

Proud to host the 1st International Symposium on Geroscience at CEU! 💙🔬 Don’t miss it: amazing speakers, cutting-edge science… and FREE registration! 🚀🙌 #Geroscience @CienciaUCHCEU

🧬 What if we could read how fast we’re ageing? a molecular “clock” that tracks ageing across humans and other mammals using gene activity—and can even hint at lifespan and health.?? The biology of ageing is more universal than we thought. 🔬 nature.com/articles/s41586-0…

Wonderful perspective by Tiarnan Keenan, Emily Chew, and colleagues about when to take AREDS2 supplements or consume Mediterranean diet for different stages of age-related macular degeneration. sciencedirect.com/science/ar…

Plants live off light, capturing its energy through photosynthesis to make food, but we lack the molecular machinery to do the same. Now, a research team has tricked out lab-grown mouse and human cells with photosynthetic structures—not for nourishment, but to create a treatment for a common, painful condition called dry eye. scim.ag/4ddLRuZ

Earlier this week I posted an example of a fake western blot provided by ThermoFisher to demonstrate the validity of a p53 antibody. I considered it an amusing curiosity. In fact ThermoFisher has systematically manipulated antibody validation data. Short Thread... 🧵

Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan. nature.com/articles/s41586-0… 59 loci. Two decades of data. Thread 👇 #Longevity #Aging #Genetics #Healthspan

What are GLP-1s actually doing? In my latest for the @nytopinion, I explore how patients experience these drugs & why the story may be more complex than many assume. nytimes.com/interactive/2026… feat. insights from @DanielJDrucker @seeleyrj @BevTchangMD among many others #glp1

🦔A researcher invented a fake eye condition called bixonimania, uploaded two obviously fraudulent papers about it to an academic server, and watched major AI systems present it as real medicine within weeks. The fake papers thanked Starfleet Academy, cited funding from the Professor Sideshow Bob Foundation and the University of Fellowship of the Ring, and stated mid-paper that the entire thing was made up. Google's Gemini told users it was caused by blue light. Perplexity cited its prevalence at one in 90,000 people. ChatGPT advised users whether their symptoms matched. The fake research was then cited in a peer-reviewed journal that only retracted it after Nature contacted the publisher. My Take The researcher made the papers as obviously fake as possible on purpose. The AI systems didn't catch it. Neither did the human researchers who cited it in real journals, which means people are feeding AI-generated references into their work without reading what they're actually citing. I've covered the FDA using AI for drug review, the NYC hospital CEO ready to replace radiologists, and ChatGPT Health launching this year. All of that is happening in the same environment where a condition funded by a Simpsons character and endorsed by the crew of the Enterprise was being presented as emerging medical consensus. The people making these deployment decisions seem to believe the pipeline from research to AI to patient is more supervised than it actually is. This experiment suggests it isn't supervised much at all. Hedgie🤗 nature.com/articles/d41586-0…

Earthset. The Artemis II crew captured this view of an Earthset on April 6, 2026, as they flew around the Moon. The image is reminiscent of the iconic Earthrise image taken by astronaut Bill Anders 58 years earlier as the Apollo 8 crew flew around the Moon.

Will cell reprogramming with stem cell factors reverse aging? A pilot trial in eye disease will soon be the first test at the tissue level. nature.com/articles/d41586-0… Feature @Nature by @heidiledford @altos_labs @lifebiosciences

an exciting new #phd opportunity in collaboration with @CampagnoloLab funded by @fightforsightUK on #circadian coupling between #pericytes and #endothelial cells of the #retina findaphd.com/phds/project/re…

So the question is not only: where do resident macrophages come from? It is also: when does self-maintenance become durable, and when does it fail to do so? That is the problem Establishment Kinetics is meant to solve. Full paper in Advances in Immunology sciencedirect.com/science/ch…

Please enjoy the latest publication from our lab "Restriction of Individual Branched-Chain Amino Acids has Distinct Effects on the Development and Progression of Alzheimer's Disease in 3xTg Mice"

Malia Edwards et al from Wilmer Eye Institute @HopkinsMedicine describe choroidal vascular findings in a case of multifocal geographic atrophy using histology & immunohistochemistry & correlating the findings with multimodal clinical imaging @AMD_histo_lab doi.org/10.1167/iovs.67.3.19